The role of topotecan in cancer ginecology treatment
The high morbidity, often latent, asymptomatic disease development is not optimal therapy in the first line, causes the development of the frequent recurrence of tumors, requiring second and thirds lines of chemotherapy. The use of topotecan in standard mode is limited by myelosuppression, therefore...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2017-02-01
|
| Series: | Опухоли женской репродуктивной системы |
| Subjects: | |
| Online Access: | https://ojrs.abvpress.ru/ojrs/article/view/525 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839570919772651520 |
|---|---|
| author | A. G. Kedrova V. V. Kosyy D. A. Astakhov |
| author_facet | A. G. Kedrova V. V. Kosyy D. A. Astakhov |
| author_sort | A. G. Kedrova |
| collection | DOAJ |
| description | The high morbidity, often latent, asymptomatic disease development is not optimal therapy in the first line, causes the development of the frequent recurrence of tumors, requiring second and thirds lines of chemotherapy. The use of topotecan in standard mode is limited by myelosuppression, therefore the new regimes are studied. To reduce the hematologic toxicity is recommended weekly injection of 4 mg/m2 in 1, 8, 15 days of a 28-day cycle of therapy, as its effectiveness is comparable to the effectiveness of the standard 5-day regime. We determined the toxicity and efficacy of combined weekly topotecan and bevacizumab in patients with secondary platinumresistant ovarian, peritoneal, fallopian tube, endometrium and cervix cancer. Patients were treated topotecan 3,5–4 mg/m2 and bevacizumab 7 mg/kg on days 1, 8, and 15 of a 28-day cycle until progressive disease or excessive toxicity. The primary end point was efficacy and toxicity.Combination on weekly topotecan and bevacizumab showed acceptable toxicity and encouraging efficacy in patients with platinum-resistant tumors. |
| format | Article |
| id | doaj-art-5cb15d5fb500443a88086086200d2f97 |
| institution | Matheson Library |
| issn | 1994-4098 1999-8627 |
| language | Russian |
| publishDate | 2017-02-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Опухоли женской репродуктивной системы |
| spelling | doaj-art-5cb15d5fb500443a88086086200d2f972025-08-04T14:33:40ZrusABV-pressОпухоли женской репродуктивной системы1994-40981999-86272017-02-01124525610.17650/1994-4098-2016-12-4-52-56521The role of topotecan in cancer ginecology treatmentA. G. Kedrova0V. V. Kosyy1D. A. Astakhov2Institute for Advanced Training, Federal Biomedical Agency of Russia; Federal Research and Clinical Center, Federal Biomedical Agency of RussiaFederal Research and Clinical Center, Federal Biomedical Agency of RussiaFederal Research and Clinical Center, Federal Biomedical Agency of RussiaThe high morbidity, often latent, asymptomatic disease development is not optimal therapy in the first line, causes the development of the frequent recurrence of tumors, requiring second and thirds lines of chemotherapy. The use of topotecan in standard mode is limited by myelosuppression, therefore the new regimes are studied. To reduce the hematologic toxicity is recommended weekly injection of 4 mg/m2 in 1, 8, 15 days of a 28-day cycle of therapy, as its effectiveness is comparable to the effectiveness of the standard 5-day regime. We determined the toxicity and efficacy of combined weekly topotecan and bevacizumab in patients with secondary platinumresistant ovarian, peritoneal, fallopian tube, endometrium and cervix cancer. Patients were treated topotecan 3,5–4 mg/m2 and bevacizumab 7 mg/kg on days 1, 8, and 15 of a 28-day cycle until progressive disease or excessive toxicity. The primary end point was efficacy and toxicity.Combination on weekly topotecan and bevacizumab showed acceptable toxicity and encouraging efficacy in patients with platinum-resistant tumors.https://ojrs.abvpress.ru/ojrs/article/view/525relapse of ovarian cancerendometrium cancercervix cancertopotecanbevacizumabweekly regimen |
| spellingShingle | A. G. Kedrova V. V. Kosyy D. A. Astakhov The role of topotecan in cancer ginecology treatment Опухоли женской репродуктивной системы relapse of ovarian cancer endometrium cancer cervix cancer topotecan bevacizumab weekly regimen |
| title | The role of topotecan in cancer ginecology treatment |
| title_full | The role of topotecan in cancer ginecology treatment |
| title_fullStr | The role of topotecan in cancer ginecology treatment |
| title_full_unstemmed | The role of topotecan in cancer ginecology treatment |
| title_short | The role of topotecan in cancer ginecology treatment |
| title_sort | role of topotecan in cancer ginecology treatment |
| topic | relapse of ovarian cancer endometrium cancer cervix cancer topotecan bevacizumab weekly regimen |
| url | https://ojrs.abvpress.ru/ojrs/article/view/525 |
| work_keys_str_mv | AT agkedrova theroleoftopotecanincancerginecologytreatment AT vvkosyy theroleoftopotecanincancerginecologytreatment AT daastakhov theroleoftopotecanincancerginecologytreatment AT agkedrova roleoftopotecanincancerginecologytreatment AT vvkosyy roleoftopotecanincancerginecologytreatment AT daastakhov roleoftopotecanincancerginecologytreatment |